Cargando…
Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants
BACKGROUND: Rabbit antithymocyte globulin (rATG, Thymoglobulin®) is the most common induction immunosuppression therapy in kidney transplantation. We applied a database integration strategy to capture and compare long-term (10-year) outcome data for US participants in a clinical trial of rATG versus...
Autores principales: | Lentine, Krista L., Schnitzler, Mark A., Xiao, Huiling, Brennan, Daniel C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545548/ https://www.ncbi.nlm.nih.gov/pubmed/26285695 http://dx.doi.org/10.1186/s13063-015-0891-y |
Ejemplares similares
-
Erratum to: Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10–10 Study participants
por: Lentine, Krista L., et al.
Publicado: (2015) -
Clinical Correlates and Outcomes of Dual Basiliximab and Antithymocyte Globulin Induction in Kidney Transplant Recipients: A National Study
por: Lam, Ngan N., et al.
Publicado: (2021) -
Tailored Rabbit Antithymocyte Globulin Induction Dosing for Kidney Transplantation
por: Singh, Namita, et al.
Publicado: (2018) -
Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin
por: Jeong, Rachel, et al.
Publicado: (2020) -
Retrospective Evaluation of Rabbit Antithymocyte Globulin Induction in Heart Transplant Patients
por: Lee, Grace Pui-Yun, et al.
Publicado: (2022)